Work

CaDAnCe-302, a phase 3, open-label, randomized study of BGB-16673 compared with idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma previously exposed to both a BTK and BCL2 inhibitor

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-8245

Authors: Constantine Tam, John Seymour, Jiayi Shen, Jan Michel, Maryam Sarraf Yazdy, Patrick Brown, Shelonitda Rose, Motohisa Takai, Meghan Thompson, Mark-David Levin, Talha Munir, Paolo Ghia, Jeff Sharman

Institutions: The Alfred Hospital, Monash University, The Royal Melbourne Hospital, The University of Melbourne, Peter MacCallum Cancer Centre, Memorial Sloan Kettering Cancer Center, Albert Schweitzer Ziekenhuis, Leeds Teaching Hospitals NHS Trust, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, Willamette Valley Cancer Institute and Research Center

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417016308

Cites:

Cited by:

Related to: